San Diego and Richmond, Va., USA, Ljubljana, Slovenia, and Sydney, Australia, November 19, 2015 – Link here. AmpliPhi Biosciences Corporation (NYSEMKT: APHB), a global leader in the development of bacteriophage-based antibacterial therapies to treat drug-resistant infections, today announced that it has entered into a Clinical Trial Research Agreement with the University of Adelaide for the purpose of conducting a […]

Company Announces One-for-Fifty Reverse Stock Split Shares of Common Stock Will Begin Trading on a Split-Adjusted Basis on August 07, 2015 San Diego and Richmond, VA, USA, Ljubljana, Slovenia, and Sydney, Australia, August 04, 2015 –Linkhere. AmpliPhi BioSciences Corporation (OTCQB: APHB), a global leader in developing bacteriophage-based antibacterial therapies to treat drug resistant infections, today […]

Results to be presented at the 38th European Cystic Fibrosis Conference. Link here. San Diego and Richmond, VA, USA, Ljubljana, Slovenia, and Sydney, Australia, June 8, 2015 – AmpliPhi BioSciences Corporation (OTCQB: APHB), a global leader in the development of bacteriophage-based antibacterial therapies to treat drug resistant infections, today announced that new data on the activity of […]

San Diego and Richmond, VA, USA, Ljubljana, Slovenia, and Sydney, Australia, May 19 2015 Link here. AmpliPhi BioSciences Corporation (OTCQB: APHB), a global leader in the development of bacteriophage-based antibacterial therapies to treat drug resistant infections, today provided a corporate update and announced financial results for the first quarter ended March 31, 2015. Corporate Update • […]

RICHMOND, Va. & LJUBLJANA, Slovenia, & SYDNEY — March 31, 2015. Link here. Richmond, VA, USA, Ljubljana, Slovenia, and Sydney, Australia, March 31, 2015 – AmpliPhi BioSciences Corporation. (OTCQB: APHB), the global leader in developing bacteriophage-based antibacterial therapies to treat drug resistant infections, today announced that the European Patent Office (EPO) has granted European patent no. EP […]